All In Biotech

Drug Trial Radar · NCT05438459

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

Clinical Trial of Repeated Intraperitoneal Administration of GAIA-102 in Patients With Advanced Gastrointestinal Cancer (Gastric Cancer / Pancreatic Cancer) of Microsatellite Stable (MSS) With Malignant Ascites (Phase I / II Investigator-initiated Clinical Trial) (GAIA-102-PD Clinical Trial)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Jun 8, 2022

Primary completion

Mar 31, 2032

Study completion Mar 31, 2032

Sponsor

Lead sponsor
Kyushu UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GAIA BioMedicine Inc.; Japan Agency for Medical Research and Development
First posted
Jun 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I Part : Confirm the safety of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination for advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended number of doses for Phase II part. Phase II Part(Gastric Cancer):Comparative Study Research the efficacy and safety of as a monotherapy or GAIA-102 and pembrolizumab for advanced gastrointestinal cancer of microsatellite stable with malignant ascites at the recommended dose of GAIA-102 decided in the Phase I part. Phase II Part (Pancreatic Cancer): Comparative Study Including a Run-in Cohort Research the efficacy and safety of a combination regimen of GAIA-102 and pembrolizumab added to existing chemotherapy (standard of care) for microsatellite stable advanced pancreatic cancer with malignant ascites at the recommended dosing frequency of GAIA-102 decided in the Phase I part.

Conditions

  • Gastric Cancer
  • Pancreatic Cancer

Interventions

  • GAIA-102Biological

    GAIA-102: 1 vial (2 x 10\^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.

  • GAIA-102Biological

    GAIA-102: 1 vial (2 x 10\^8 cells) as dose at a fixed dose, on 3 times by weekly for 3 consecutive weeks.

  • PembrolizumabDrug

    Pembrolizumab 200 mg administered on Day 1.

  • PembrolizumabDrug

    Pembrolizumab 200 mg administered on Day 8.

  • Trifluridine/tipiracil hydrochloride (FTD/TPI)Drug

    Trifluridine/tipiracil hydrochloride (FTD/TPI) will be administered orally twice daily for 5 consecutive days, followed by a 2-day rest period. This cycle will be repeated twice, followed by a 14-day rest period. One course consists of this schedule, and the treatment will be repeated in cycles.

  • Irinotecan hydrochloride hydrateDrug

    Intravenous infusion of 70 mg/m² (based on body surface area) over 90 minutes at 2-week intervals.

  • Calcium levofolinate hydrateDrug

    Intravenous infusion of 200 mg/m² (based on body surface area) over 2 hours.

  • FluorouracilDrug

    Immediately after completion of the calcium levofolinate hydrate intravenous infusion, fluorouracil 400 mg/m² (based on body surface area) will be administered by intravenous injection, followed by a continuous intravenous infusion of fluorouracil 2,400 mg/m² (based on body surface area) over 46 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants of Dose Limiting Toxicity (DLT) with GAIA-102 (Phase I)Time frame: Cycle 1 (Cycle period is 28 days)
  2. Frequency and severity of adverse events(Phase I)Time frame: 2 year
  3. Overall survival in patients with gastric cancer (Phase II)Time frame: up to 4 years
  4. Overall survival in patients with pancreatic cancer (PhaseⅡ)Time frame: up to 5 years(up to 5.5 years for the Run-in Cohort)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.